Crown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
28.4.2022 19:20:00 EEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006002/en/
The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.
“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”
Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.
Read the full paper here: https://go.nature.com/3LhuAAy
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug screening services and access to its living organoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research institutions including the Hubrecht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also collaborated in data for this publication. The consortium set out to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006002/en/
Contact information
Media Enquiries
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Lenovo Service Delivers Always-On Infrastructure: Premier Support Plus for Servers Powered by Proactive, AI-Driven Support26.2.2026 16:00:00 EET | Press release
Lenovo today announced the availability of Lenovo Premier Support Plus for Servers, a new premium support offering designed to help enterprises reduce downtime, simplify IT operations, and keep mission-critical infrastructure always ready. Built for today’s always-on environments, Premier Support Plus combines AI-driven proactive and predictive support, preventative maintenance, 24/7 access to Lenovo experts, and designated Service Engagement Managers to help organizations move from reactive issue resolution to proactive system care. As digital operations continue to expand and infrastructure environments grow more complex, IT teams are under increasing pressure to maintain uptime while managing limited resources. Traditional, reactive support models can lead to extended outages, repeated issues, and unpredictable costs. Lenovo Premier Support Plus for Servers addresses these challenges by identifying potential issues early and resolving them before they impact business operations. “Wi
Sitetracker Closes 2025 with Strong Momentum, Product Expansion, and a Clear Path into 202626.2.2026 16:00:00 EET | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced strong year-end results for 2025, marked by continued customer growth, expansion into new infrastructure markets, and major product innovations across operations, maintenance, and financial management. As infrastructure owners and operators face growing pressure to scale without adding headcount, Sitetracker enters 2026 positioned to help customers operate smarter, move faster, and unlock greater productivity. 2025 Highlights In 2025, Sitetracker delivered another year of growth and execution across its global customer base: Customer growth and market expansion: Sitetracker now serves more than 400 customers globally, supporting organizations across digital infrastructure, renewables, EV charging, utilities, and emerging infrastructure markets including data centers. Enhanced Operations & Maintenance capabilities: Sitetracker now connects field operations and work order ma
Proxima Fusion, RWE, the Free State of Bavaria and Max Planck Institute for Plasma Physics Sign Agreement to Build the World’s First Commercial Fusion Power Plant in Europe26.2.2026 15:15:00 EET | Press release
Proxima Fusion, Europe’s fastest-growing fusion energy company, has signed an agreement with the Free State of Bavaria, RWE, and Max Planck Institute for Plasma Physics (IPP) to put the world’s first commercial stellarator fusion power plant on the grid in Europe. Roadmap to a commercial fusion power plant begins with Alpha The Memorandum of Understanding (MoU) outlines a roadmap to commercial fusion in Europe that begins with building demonstration stellarator Alpha near the Max Planck Institute for Plasma Physics (IPP) in Garching. When operational in the 2030s, Alpha will become the first stellarator to demonstrate net energy gain, meaning its plasma will generate more energy than it consumes. The demonstration stellarator will additionally allow Proxima and its partners to test and validate key fusion technologies under real-world conditions and in shorter development cycles, accelerating the path to building the first stellarator fusion power plant, Stellaris. Site secured for Ste
NTT DATA and Ericsson Team Up to Scale Private 5G and Physical AI for Enterprises26.2.2026 15:00:00 EET | Press release
NTT DATA, a global leader in AI, digital business and technology services, and Ericsson (NASDAQ: ERIC) today announced a multi-year strategic partnership to accelerate enterprise adoption of private 5G and unlock advanced edge AI and physical AI use cases. As organizations look to embed intelligence at the edge across global operations, the partnership will enable AI-driven, outcome-focused transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226356511/en/ NTT DATA x Ericsson By combining Ericsson’s Private 5G and Edge platforms with NTT DATA’s full-stack enterprise network services, wireless network expertise, IT/OT security and managed services, the companies will deliver industry-ready solutions that help enterprises deploy private 5G networks and deliver business outcomes at a global scale with confidence. The partnership will focus on four priority areas: Global Private 5G managed services at scale: NTT DAT
Telekom Srbija Group Secures Landmark International Credit Ratings from Fitch and Moody’s, Marking Historic First for Western Balkans26.2.2026 14:22:00 EET | Press release
Telekom Srbija Group today announced that it has received international credit ratings from Fitch Ratings and Moody’s Investors Service, marking a historic milestone as the first company headquartered in the Western Balkans to achieve this distinction. Fitch Ratings has affirmed Telekom Srbija’s long-term issuer rating in connection with its debut issuance of bonds on the international financial market, recognizing the Group’s strong market position, resilient cash flow profile and disciplined financial strategy. Moody’s Investors Service has assigned a B1 rating to the company’s bond issuance, underscoring Telekom Srbija’s established operating performance and strategic importance within the regional telecommunications sector. As the first Western Balkans–headquartered company to issue bonds on the international financial market and secure ratings from two of the world’s leading credit rating agencies, Telekom Srbija has set a new benchmark for the region’s corporate sector. The achie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom